Odyssey Therapeutics (NASDAQ:ODTX) Stock Picked Up by Analysts at HC Wainwright

Analysts at HC Wainwright started coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a research note issued on Friday, Benzinga reports. The firm set a “buy” rating and a $40.00 price target on the stock. HC Wainwright‘s price objective would indicate a potential upside of 111.86% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. UBS Group started coverage on Odyssey Therapeutics in a report on Monday, October 12th. They set a “buy” rating and a $27.00 price target on the stock. Raymond James Financial assumed coverage on Odyssey Therapeutics in a report on Thursday, October 8th. They issued an “outperform” rating and a $42.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings initiated coverage on Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a “sell (d+)” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Odyssey Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $34.67.

Odyssey Therapeutics Trading Down 3.2%

Shares of NASDAQ ODTX opened at $18.88 on Friday. The company’s 50-day moving average is $21.31. Odyssey Therapeutics has a 52-week low of $15.10 and a 52-week high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. On average, equities research analysts forecast that Odyssey Therapeutics will post -6.08 earnings per share for the current fiscal year.

Institutional Trading of Odyssey Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company purchased a new position in shares of Odyssey Therapeutics during the 2nd quarter worth $601,000. State Street Corp bought a new stake in shares of Odyssey Therapeutics during the 2nd quarter valued at $1,477,000. Finally, Citadel Advisors LLC bought a new stake in shares of Odyssey Therapeutics during the 2nd quarter valued at $4,162,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.